Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Consulting agrmnt
Appointed director
Notes underwriting agrmnt
Director departure
|
|
Bone Biologics Corp (BBLG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/05/2023 |
8-K
| Other Events Interactive Data |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/19/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 12/21/2022 |
8-K
| Quarterly results |
| 11/21/2022 |
8-K
| Quarterly results |
| 10/25/2022 |
8-K
| Quarterly results |
| 10/13/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"FORM OF SERIES A WARRANT BONE BIOLOGICS CORPORATION SERIES A COMMON STOCK PURCHASE WARRANT Warrant Shares: _______ Initial Exercise Date: October 12, 2022 THIS SERIES A COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on October 12, 2027 but not thereafter, to subscribe for and purchase from Bone Biologics Corporation, a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant shall initially be issued and maintained in th...",
"FORM OF SERIES B WARRANT BONE BIOLOGICS CORPORATION SERIES B COMMON STOCK PURCHASE WARRANT Warrant Shares: _______ Initial Exercise Date: October 12, 2022 THIS SERIES B COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on October 12, 2027 but not thereafter, to subscribe for and purchase from Bone Biologics Corporation, a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant shall initially be issued and maintained in th...",
"FORM OF SERIES C WARRANT BONE BIOLOGICS CORPORATION SERIES C COMMON STOCK PURCHASE WARRANT Warrant Shares: _______ Initial Exercise Date: October 12, 2022 THIS SERIES C COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and on or prior to 5:00 p.m. on October 12, 2027 but not thereafter, to subscribe for and purchase from Bone Biologics Corporation, a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant shall initially be issued and maintained in th...",
"Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering" |
|
| 10/11/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 3,777,778 Units Consisting of 3,777,778 Shares of Common Stock, And 3,777,778 Series A Warrants to Purchase 3,777,778 Shares of Common Stock And 3,777,778 Series B Warrants to Purchase 3,777,778 Shares of Common Stock And 3,777,778 Series C Warrants to Purchase 3,777,778 Shares of Common Stock October 7, 2022 WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311",
"WARRANT AGENT AGREEMENT This Warrant Agent Agreement , dated as of October 7, 2022 between Bone Biologics Corp., a company incorporated under the laws of the State of Delaware , and Equiniti Trust Company, a limited trust company organized under the laws of the State of New York . WHEREAS, pursuant to the terms of that certain Underwriting Agreement , dated October 7, 2022, by and among the Company and WallachBeth Capital, LLC, as representatives of the underwriters set forth therein, the Company is engaged in a public offering of up to 3,777,778 Units, each Unit consisting of: one share of common stock, par value $0.001 per share of the Company; one Series A Warrant to purchase one share of Common Stock ; one Series B Warrant to purchase one share of Common Stock and; one Series C Warrant...",
"Bone Biologics Prices $5,100,000 Underwritten Public Offering" |
|
| 08/23/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/09/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
8-K
| Quarterly results |
| 03/08/2022 |
8-K
| Quarterly results |
| 12/22/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 10/19/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"[FORM OF CERTIFICATED WARRANT] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1 OF THIS WARRANT. BONE BIOLOGICS CORPORATION Warrant To Purchase Common Stock Warrant No.: Date of Issuance: [ ], 2021 Bone Biologics Corporation, a Delaware corporation , hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [BUYER], the registered holder hereof or its permitted assigns , is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price then in effect, upon exercise of this Warrant to Purchase shares of Common Stock , at any time or times on or after the Issuance Date, but not after 11:...",
"About Bone Biologics" |
|
| 10/15/2021 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...|
Docs:
|
"BONE BIOLOGICS CORPORATION UNDERWRITING AGREEMENT 1,510,455 Units Consisting of 1,510,455 Shares of Common Stock And 1,510,455 Warrants to Purchase 1,510,455 Shares of Common Stock October 13, 2021 WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311",
"WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT dated as of [ ], 2021 between Bone Biologics Corporation, a Delaware corporation , and Equiniti ___ . WHEREAS, pursuant to the terms of that certain Underwriting Agreement , dated [ ], 2021, by and among the Company and WallachBeth Capital, LLC, as representative of the underwriters set forth therein , the Company is engaged in a public offering of up to [ ] units with each Unit consisting of one share of common stock, par value $0.0001 per share of the Company and one warrant to purchase one share of Common Stock at an exercise price of $[ ] per share, including Shares and Warrants issuable pursuant to the underwriters’ over-allotment option; WHEREAS, the Company has filed with the Securities and Exchange Commission a Registration Statement ...",
"About Bone Biologics" |
|
| 06/07/2021 |
8-K
| Quarterly results |
| 09/25/2019 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 06/28/2019 |
8-K
| Quarterly results |
| 04/16/2019 |
8-K
| Quarterly results |
| 03/25/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 09/14/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 08/06/2018 |
8-K
| Resignation/termination of a director |
| 07/19/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Depart... |
| 06/12/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits|
Docs:
|
"Securities Purchase Agreement with Hankey Capital, LLC",
"Form of Convertible Secured Note",
"Second Amendment to Convertible Secured Term Note (October 24, 2014 Note) with Hankey Capital, LLC",
"Second Amendment to Convertible Secured Term Note (May 4, 2015 Note) with Hankey Capital, LLC",
"First Amendment to Convertible Secured Term Note (February 24, 2016 Note) with Hankey Capital, LLC" |
|
| 05/14/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 03/29/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Subscription Agreement with Orthofix Holdings, Inc",
"BONE BIOLOGICS COMPLETES $500,000 OF FINANCING BURLINGTON, MA – Bone Biologics , a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $500,000 funding with Orthofix Holding, Inc. The funding represents the second round of a previously announced private placement. The securities offered have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. About Bone Biologics Bone Biologics was founded to pursue regenerative medicine for bone. Bone Biologics Corporation is undertaking groundbreaking work with the three founders ..." |
|
| 12/11/2017 |
8-K
| Changes in Registrant's Certifying Accountant |
| 08/23/2017 |
8-K
| Quarterly results |
| 08/22/2017 |
8-K
| Quarterly results |
| 08/03/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/24/2017 |
8-K
| Form 8-K - Current report: |
| 06/08/2017 |
8-K
| Form 8-K - Current report |
| 05/25/2017 |
8-K
| Form 8-K - Current report |
|
|
|